These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31889652)

  • 1. The design and evaluation of a pilot covisit model: Integration of a pharmacist into a primary care team.
    Roll A; Pattison D; Baumgartner R; Sublett L; Brown B
    J Am Pharm Assoc (2003); 2020; 60(3):491-496. PubMed ID: 31889652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a pharmacist-physician covisit model in a family medicine practice.
    Ulrich IP; Patel S; Gilmer B
    J Am Pharm Assoc (2003); 2019; 59(1):129-135. PubMed ID: 30416066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Physician-Pharmacist Covisits at a Primary Care Clinic in Patients With Uncontrolled Diabetes.
    Peterson J; Hinds A; Garza A; Barner J; Hill L; Nguyen M; Lai P; Gums T
    J Pharm Pract; 2020 Jun; 33(3):321-325. PubMed ID: 30428760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Impact of a Pharmacist-Led Telehealth Clinic on Diabetes-Related Goals of Therapy in a Veteran Population.
    Maxwell LG; McFarland MS; Baker JW; Cassidy RF
    Pharmacotherapy; 2016 Mar; 36(3):348-56. PubMed ID: 26877253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of a pharmacist + health coach chronic disease management program in a rural free clinic.
    Hurst H; Dunn S; Fuji KT; Gilmore J; Wilt S; Webster S; Parikh P
    J Am Pharm Assoc (2003); 2021; 61(4):442-449. PubMed ID: 33775539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to clinical pharmacy services in a pharmacist-physician covisit model.
    Ulrich IP; Lugo B; Hughes P; Doucette L; Creith BB; Flanagan S; Gilmer B
    Res Social Adm Pharm; 2021 Jul; 17(7):1321-1326. PubMed ID: 33153913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacist-provided diabetes management and education via a telemonitoring program.
    Shane-McWhorter L; McAdam-Marx C; Lenert L; Petersen M; Woolsey S; Coursey JM; Whittaker TC; Hyer C; LaMarche D; Carroll P; Chuy L
    J Am Pharm Assoc (2003); 2015; 55(5):516-26. PubMed ID: 26359961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sustainable business model for comprehensive medication management in a patient-centered medical home.
    Fabel PH; Wagner T; Ziegler B; Fleming PA; Davis RE
    J Am Pharm Assoc (2003); 2019; 59(2):285-290. PubMed ID: 30611660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of a pharmacist-driven, collaborative practice on diabetes management in an Urban underserved population: a mixed method assessment.
    Ray S; Lokken J; Whyte C; Baumann A; Oldani M
    J Interprof Care; 2020; 34(1):27-35. PubMed ID: 31381470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Chronic Disease Outcomes Through Medication Therapy Management in Federally Qualified Health Centers.
    Rodis JL; Sevin A; Awad MH; Porter B; Glasgow K; Hornbeck Fox C; Pryor B
    J Prim Care Community Health; 2017 Oct; 8(4):324-331. PubMed ID: 28381095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacists' impact on improving outcomes in patients with type 2 diabetes mellitus.
    Pepper MJ; Mallory N; Coker TN; Chaki A; Sando KR
    Diabetes Educ; 2012; 38(3):409-16. PubMed ID: 22523190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of clinical pharmacist intervention on diabetes-related outcomes in a military treatment facility.
    Wallgren S; Berry-Cabán CS; Bowers L
    Ann Pharmacother; 2012 Mar; 46(3):353-7. PubMed ID: 22395249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic analysis of the diabetes initiative program: a pharmacist-physician collaborative care model.
    Franklin BE; Farland MZ; Thomas J; McFarland MS; Ray SM; Byrd DC
    Ann Pharmacother; 2013 Dec; 47(12):1627-34. PubMed ID: 24259610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacists in Federally Qualified Health Centers: Models of Care to Improve Chronic Disease.
    Rodis JL; Capesius TR; Rainey JT; Awad MH; Fox CH
    Prev Chronic Dis; 2019 Nov; 16():E153. PubMed ID: 31753083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of pharmacist consults within a collaborative enhanced primary care team model to improve diabetes care.
    Firkus D; McCoy RG; Matulis J; Kessler M; Mara K; Herges J
    PLoS One; 2023; 18(1):e0280654. PubMed ID: 36662741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of pharmacists into patient-centered medical homes in federally qualified health centers in Texas.
    Wong SL; Barner JC; Sucic K; Nguyen M; Rascati KL
    J Am Pharm Assoc (2003); 2017; 57(3):375-381. PubMed ID: 28506398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Federal Bureau of Prisons clinical pharmacy program improves patient A1C.
    Bingham JT; Mallette JJ
    J Am Pharm Assoc (2003); 2016; 56(2):173-7. PubMed ID: 27000168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of clinical pharmacist management of type 2 diabetes versus usual care in a federally qualified health center.
    Fink RM; Mooney EV; Saseen JJ; Billups SJ
    Pharm Pract (Granada); 2019; 17(4):1618. PubMed ID: 31897259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving outcomes for diverse populations disproportionately affected by diabetes: final results of Project IMPACT: Diabetes.
    Bluml BM; Watson LL; Skelton JB; Manolakis PG; Brock KA
    J Am Pharm Assoc (2003); 2014; 54(5):477-85. PubMed ID: 25216877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study.
    Jacobs M; Sherry PS; Taylor LM; Amato M; Tataronis GR; Cushing G
    J Am Pharm Assoc (2003); 2012; 52(5):613-21. PubMed ID: 23023841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.